Skip to main content
Advertisement
GLP-1 / Ozempic Claims

Ozempic & GLP-1 Drug Injuries

GLP-1 medications including Ozempic, Wegovy, Mounjaro, and others have been linked to serious gastrointestinal injuries and vision loss. Over 3,400 cases are pending in federal court.

Medications

Which Drugs Are Included

The following GLP-1 receptor agonist medications are included in the current litigation:

Ozempic

Semaglutide — manufactured by Novo Nordisk. Approved for type 2 diabetes.

Wegovy

Semaglutide — manufactured by Novo Nordisk. Approved for chronic weight management.

Mounjaro

Tirzepatide — manufactured by Eli Lilly. Approved for type 2 diabetes.

Saxenda

Liraglutide — manufactured by Novo Nordisk. Approved for chronic weight management.

Rybelsus

Semaglutide (oral) — manufactured by Novo Nordisk. Approved for type 2 diabetes.

Trulicity

Dulaglutide — manufactured by Eli Lilly. Approved for type 2 diabetes.

Injuries

Qualifying Injuries

Two categories of injuries are currently the subject of federal litigation against GLP-1 drug manufacturers:

Gastrointestinal Injuries

  • Gastroparesis (stomach paralysis)
  • Bowel obstruction / ileus
  • Pancreatitis
  • Gallbladder disease / removal

Vision Loss

  • NAION (non-arteritic anterior ischemic optic neuropathy)
  • Sudden vision loss or impairment
Litigation

Current Litigation Status

GLP-1 injury lawsuits are currently consolidated in two separate multidistrict litigations (MDLs) in the Eastern District of Pennsylvania:

MDL 3094 — Gastrointestinal

Approximately 3,363 pending cases involving gastroparesis, bowel obstruction, pancreatitis, and other GI injuries. Cases consolidated in the Eastern District of Pennsylvania.

MDL 3163 — Vision Loss

Approximately 54 pending cases involving NAION and other vision loss injuries. Cases consolidated in the Eastern District of Pennsylvania.

Bellwether trials are expected in late 2026 or early 2027. No settlements have been reached yet — the litigation is in its early stages. The outcome of initial trials will likely shape how thousands of remaining cases are resolved.

Eligibility

Do You Qualify?

You may be eligible to file a GLP-1 injury claim if the following apply:

Used an FDA-Approved GLP-1 Medication

You were prescribed and used Ozempic, Wegovy, Mounjaro, Saxenda, Rybelsus, Trulicity, or another GLP-1 receptor agonist.

Diagnosed with a Qualifying Injury

You were diagnosed with gastroparesis, bowel obstruction, pancreatitis, gallbladder disease, NAION, or other serious injury after starting the medication.

Have Medical Documentation

You have medical records documenting your injury and its connection to GLP-1 medication use.

Not Already Represented

You are not currently represented by another attorney for this specific claim.

Common Questions

Frequently Asked Questions

Which GLP-1 medications are included in the lawsuits?

The litigation covers multiple GLP-1 receptor agonist medications including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Saxenda (liraglutide), Rybelsus (semaglutide), and Trulicity (dulaglutide). Both brand-name and generic versions may be included.

What injuries qualify for a GLP-1 lawsuit?

Qualifying injuries fall into two main categories: gastrointestinal injuries (gastroparesis, bowel obstruction, ileus, pancreatitis, gallbladder disease or removal) and vision loss (NAION — non-arteritic anterior ischemic optic neuropathy). The injury must have occurred after starting a GLP-1 medication.

How long do I have to file a claim?

The statute of limitations varies by state and can range from one to several years from the date of injury or discovery. Because deadlines vary and new information continues to emerge, it is important to have your case evaluated as soon as possible to preserve your legal rights.

What is the current status of the Ozempic litigation?

Gastrointestinal injury cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania with approximately 3,363 pending cases. Vision loss cases are in a separate MDL 3163, also in the Eastern District of Pennsylvania, with approximately 54 pending cases. Bellwether trials are expected in late 2026 or early 2027. No settlements have been reached yet.

Do I need to stop taking my medication to file a lawsuit?

Filing a lawsuit does not require you to stop taking your medication. Any decisions about your medical treatment should be made with your doctor. The lawsuit is about whether the manufacturer adequately warned about the risks, not about whether you should continue treatment.

What does it cost to file a claim?

There is no cost to you. Attorneys handling GLP-1 injury cases work on a contingency fee basis, meaning they only get paid if you receive compensation. The initial case review through NuLegal is completely free with no obligation.

Don't Wait

Statutes of limitations may limit how long you have to file. Get a free, no-obligation case review today to find out if you qualify for compensation.

Free Case Review

Advertisement